Last reviewed · How we verify
Recombinant Humanized Monoclonal Antibody MIL93
Recombinant Humanized Monoclonal Antibody MIL93 is a Small molecule drug developed by Beijing Mabworks Biotech Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Recombinant Humanized Monoclonal Antibody MIL93 |
|---|---|
| Sponsor | Beijing Mabworks Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant Humanized Monoclonal Antibody MIL93 CI brief — competitive landscape report
- Recombinant Humanized Monoclonal Antibody MIL93 updates RSS · CI watch RSS
- Beijing Mabworks Biotech Co., Ltd. portfolio CI
Frequently asked questions about Recombinant Humanized Monoclonal Antibody MIL93
What is Recombinant Humanized Monoclonal Antibody MIL93?
Recombinant Humanized Monoclonal Antibody MIL93 is a Small molecule drug developed by Beijing Mabworks Biotech Co., Ltd..
Who makes Recombinant Humanized Monoclonal Antibody MIL93?
Recombinant Humanized Monoclonal Antibody MIL93 is developed by Beijing Mabworks Biotech Co., Ltd. (see full Beijing Mabworks Biotech Co., Ltd. pipeline at /company/beijing-mabworks-biotech-co-ltd).
What development phase is Recombinant Humanized Monoclonal Antibody MIL93 in?
Recombinant Humanized Monoclonal Antibody MIL93 is in Phase 1.